Price
No data yet.
Social Signal Score
Analyst Ratings
30 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Zachary Roberts
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 151
- Beta
- 0.48
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -5.27
Financials
Revenue
$0.00-100.0%Net Income
$-50.37MEBITDA
$-47.40MFree Cash Flow
$-36.14M-722960.0%EPS (diluted)
$-0.15Shares Outstanding (diluted)
346.09M+686.4%Operating Expenses
$54.79MCash & Debt
$292.96MReturn of Capital
$0.00Revenue by Segment (annual)
$4.60MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-190.89M | $-0.87 |
| 2024 | $22.0K | $-257.59M | $-1.32 |
| 2023 | $95.0K | $-327.26M | $-2.09 |
| 2022 | $156.0K | $-340.41M | $-2.38 |
| 2021 | $114.09M | $-182.05M | $-1.34 |
| 2020 | $0.00 | $-250.22M | $-2.08 |
| 2019 | $0.00 | $-184.59M | $-1.83 |
| 2018 | $0.00 | $-211.50M | $-2.36 |
| 2017 | $0.00 | $-2.0K | $-0.00 |
Valuation
ALLOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+220.00%Social Signal Score
Mentions (16)
- Newsseekingalpha.com·13d ago·Positive
Allogene Therapeutics, Inc. (ALLO) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases Transcript Allogene Therapeutics, Inc. ( ALLO ) Reviews Preliminary ALLO-329 Safety and Efficacy Data in Autoimmune Diseases November 9, 2026 9:00 AM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer Zachary Roberts - President, CEO & Director Conference Call Participants Vivek Nagaraja Biren Amin - Piper Sandler & Co., Researc…
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease SOUTH SAN FRANCISCO, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced preliminary safety, efficacy and translational data from the ongoing Phase 1 RESOLUTION study evaluating ALLO-329, an inv…
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Allogene Therapeutics, Inc. (ALLO) Q3 2026 Earnings Call Transcript Allogene Therapeutics, Inc. ( ALLO ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer Zachary Roberts - President, CEO & Director Geoffrey Parker Conference Call Participants Tyler Van Buren - TD Cowen, Research Division Michael Yee - UBS Investment Bank, Research Division Jiale Song - Jefferies LLC, Research Division Saman…
View source ↗ - Newsmarketbeat.com·17d ago·Neutral
Allogene Therapeutics Q3 Earnings Call Highlights Allogene Therapeutics NASDAQ: ALLO expects to complete enrollment in its ALPHA3 lymphoma trial by the end of 2027, as increased screening and activity in Asia-Pacific help support recruitment, executives said on the company's third-quarter earnings call.
View source ↗ - Newsglobenewswire.com·17d ago·Neutral
Allogene Therapeutics Reports Third Quarter 2026 Financial Results and Business Update SOUTH SAN FRANCISCO, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended September 30, 2026.
View source ↗ - Newsglobenewswire.com·24d ago·Neutral
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data SOUTH SAN FRANCISCO, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced two November investor events highlighting third quarter 2026 results and the first clinical update from its …
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conferences in November and December 2026.
View source ↗ - Newszacks.com·72d ago·Neutral
Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound? Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newsseekingalpha.com·74d ago·Positive
Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Allogene Therapeutics, Inc. (ALLO) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that Geoffrey Parker, Executive Vice President and Chief Financial Officer, will retire effective November 6, 2026.
View source ↗ - Newsglobenewswire.com·83d ago·Neutral
Allogene Therapeutics Announces Participation in September Investor Conference SOUTH SAN FRANCISCO, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today announced that it will participate in the following upcoming investor conference in September.
View source ↗ - Newszacks.com·97d ago·Negative
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year? Here is how Allogene Therapeutics (ALLO) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.
View source ↗ - Newszacks.com·101d ago·Neutral
Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs ALLO narrows its Q2 loss as R&D costs fall, while a stronger cash position extends its runway into 2029.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript Allogene Therapeutics, Inc. (ALLO) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Neutral
Allogene Therapeutics Q2 Earnings Call Highlights Allogene Therapeutics NASDAQ: ALLO outlined progress across its clinical pipeline during its second-quarter 2026 conference call, highlighting expanded enrollment infrastructure for its pivotal ALPHA3 lymphoma study, recent FDA designations for cema-cel, published renal cell carcinoma data for ALLO-316, and plans to report initial data from the ALLO-329 autoimmune program by year-end.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2026.
View source ↗
Earnings
Thu, Mar 11(in 4 months)
Consensus estimate $-0.15 per share
Typical surprise +17.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 5$-0.15 vs $-0.15miss
- Wed, Aug 12$-0.13 vs $-0.17beat
- Wed, May 13$-0.18 vs $-0.19beat
- Thu, Mar 12$-0.17 vs $-0.25beat
- Thu, Nov 6$-0.19 vs $-0.23beat
- Wed, Aug 13$-0.23 vs $-0.28beat
Estimates and results for ALLO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ALLO officers and directors.
- Bought
- $5.0m
- Sold
- $1.2m
1 trade
31 trades
- Parker Geoffrey M.sold
- Douglas Earl Martinsold
- Yoshiyama Anniesold
- Beneski Benjamin Machinassold
- Beneski Benjamin Machinassold
- Chang David Dsold
- Beneski Benjamin Machinassold
- Beneski Benjamin Machinassold
68 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ALLO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
